ClinicalTrials.gg
TerminatedNCT00560352Updated Mar 13, 2017Results posted

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

A Phase 1 interventional study of Dasatinib and Bortezomib in Multiple Myeloma, sponsored by Bristol-Myers Squibb. Terminated at 7 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
215th of 267
16 · median 41
Started
2008
with 21 others
Phase 1
41 of 271
1 open now
Registered
75th of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 215th largest by enrollment of the 267 interventional ones that give a count, is one of 22 that started in 2008, is one of 41 in phase 1, and was the 75th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of dasatinib with bortezomib in the treatment of relapsed or refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of multiple myeloma with
  • Evidence of disease and at least 2 prior therapies for multiple myeloma
  • Performance Status of 0 - 2
  • Last treatment for multiple myeloma not within 21 days prior to study treatment initiation
  • Bone marrow transplant not within 3 months prior to study treatment initiation
  • Required baseline hematology and chemistry parameters.

Key Exclusion Criteria:

  • cardiac disease ( Class III or IV)
  • Abnormal corrected for heart rate using Fridericia's formula prolonged (>450 msec) after electrolytes have been corrected on baseline
  • Malabsorption syndrome or uncontrolled gastrointestinal toxicities
  • Dementia, chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
  • Clinically significant pleural effusion in the previous 12 months or current ascites
  • Clinically significant coagulation or function disorder
  • Intolerance to dasatinib and/or bortezomib
  • Acute diffuse infiltrative pulmonary disease
  • Prior or concurrent , except for adequately treated basal cell or squamous cell skin cancer, adequately treated Stage I or II cancer currently in complete remission, cervical carcinoma in situ, or any other cancer from which the participant has been disease-free for 3 years.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Dasatinib + Bortezomib + Dexamethasone

    Phase I dose escalation study

    Drug: Dasatinib · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD

    Also known as: Sprycel, BMS-354825

  • Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD

    Also known as: Velcade®

  • Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone

    MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended MTD is the maximum dose that the participants received.

    Time frame: Days 1 to 21

  2. MTD and Recommended MTD of Bortezomib in Combination With Dasatinib and Dexamethasone

    MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended dose is the maximum dose that the participants received.

    Time frame: Days 1 to 21

Secondary outcomes

  1. Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry

    S=serum; U=urine; MP=M-protein; ST=soft tissue, PC=plasmacytomas; IF=immunofixation; BL=baseline. RR calculated on best response any time. CR=MP undetectable by IF, ≤5% plasma cells in bone marrow, and no ST PC. VGPR=MP detectable by IF, or ≥90% drop in S MP and U MP\<100 mg/24h. PR= ≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size. MR= ≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC. SD=Not CR, VGPR, PR, or MR. PD= ≥25% rise in S or U M-component; new/increased size of bone lesions, ST PC, or hypercalcemia.

    Time frame: Day 1 until last tumor assessment (maximum reached: 9 months)

  2. Duration of Response

    Duration of response calculated for those with best response=CR (M-protein \[MP\] undetectable by immunofixation \[IF\], ≤5% plasma cells in bone marrow, no soft tissue plasmacytomas); VGPR (MP detectable by IF, or ≥90% drop in serum \[S\] MP and urine \[U\] MP\<100 mg/24h); PR(≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size); or MR (≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC). Duration of response calculated from day criteria for CR, VGPR, PR, and MR were met until progression or death, whichever came first.

    Time frame: First occurrence of response to disease progression or death, whichever occurred first (maximum reached: 12.2 months)

  3. Progression-free Survival

    Progression-free survival was defined as the time from start of treatment until progression or death, whichever occurred first. Participants were to be followed-up for 12 months following the last dose of dasatinib for progression and survival. PFS was analyzed for the all-treated population.

    Time frame: Day 1 to disease progression or death, whichever came first (maximum reached: 14 months)

  4. Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, AEs, and Drug-related AEs by Grade

    An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to or of unknown relationship to study treatment. Grade 3=severe; Grade 4=life-threatening.

    Time frame: Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months)

07

Results

Posted Jul 9, 2012
Limitations and caveats
The study was terminated due to an unexpectedly low recruitment rate, and no participants were enrolled in a planned dose-expansion phase.

Participant flow

Participant flow — Overall Study
MilestoneDasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QD
Started734
Completed000
Not completed734
Withdrew: Adverse event unrelated to study drug211
Withdrew: Study drug toxicity301
Withdrew: Disease progression011
Withdrew: Withdrawal by subject111
Withdrew: Maximum clinical benefit100

Outcome measures

PrimaryMaximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone

MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended MTD is the maximum dose that the participants received.

Time frame:
Days 1 to 21
Reported as:
Number · mg QD
Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone
mg QDAll Treated
MTD dasatinibNA
Recommended MTD dasatinib140
SecondaryBest Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry

S=serum; U=urine; MP=M-protein; ST=soft tissue, PC=plasmacytomas; IF=immunofixation; BL=baseline. RR calculated on best response any time. CR=MP undetectable by IF, ≤5% plasma cells in bone marrow, and no ST PC. VGPR=MP detectable by IF, or ≥90% drop in S MP and U MP\<100 mg/24h. PR= ≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size. MR= ≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC. SD=Not CR, VGPR, PR, or MR. PD= ≥25% rise in S or U M-component; new/increased size of bone lesions, ST PC, or hypercalcemia.

Time frame:
Day 1 until last tumor assessment (maximum reached: 9 months)
Reported as:
Number · Percentage of participants
Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry
Percentage of participantsDasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QD
Complete response (CR)000
Very good partial response (VGPR)000
Partial response (PR)14.300
Minimal response (MR)0025
Stable disease (SD)57.100
Progressive disease (PD)14.333.30
Unable to determine033.325
Not reported14.333.350
SecondaryDuration of Response

Duration of response calculated for those with best response=CR (M-protein \[MP\] undetectable by immunofixation \[IF\], ≤5% plasma cells in bone marrow, no soft tissue plasmacytomas); VGPR (MP detectable by IF, or ≥90% drop in serum \[S\] MP and urine \[U\] MP\<100 mg/24h); PR(≥50% drop in S MP and ≥90% drop in U MP or U protein \<200 mg/24h, ≥50% drop in BL ST PC size); or MR (≥25% to \<50% drop in S MP and ≥50% to \<90% drop in U MP and ≥25% to \<50% drop in BL ST PC). Duration of response calculated from day criteria for CR, VGPR, PR, and MR were met until progression or death, whichever came first.

Time frame:
First occurrence of response to disease progression or death, whichever occurred first (maximum reached: 12.2 months)
Reported as:
Number · Months
Duration of Response
MonthsDasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QD
Partial response (PR)5.4—0
Minimal response (MR)NA—12.2
SecondaryProgression-free Survival

Progression-free survival was defined as the time from start of treatment until progression or death, whichever occurred first. Participants were to be followed-up for 12 months following the last dose of dasatinib for progression and survival. PFS was analyzed for the all-treated population.

Time frame:
Day 1 to disease progression or death, whichever came first (maximum reached: 14 months)
Reported as:
Median · Months
Progression-free Survival
MonthsAll Treated
Progression-free Survival6.3 (2.4 to 14.0)
SecondaryNumber of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, AEs, and Drug-related AEs by Grade

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to or of unknown relationship to study treatment. Grade 3=severe; Grade 4=life-threatening.

Time frame:
Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months)
Reported as:
Number · Participants
Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, AEs, and Drug-related AEs by Grade
ParticipantsDasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QD
Death322
SAEs621
Drug-related SAEs200
Drug-related AEs leading to discontinuation301
AEs leading to discontinuation512
AEs734
AEs, Grades 3 and 4334
Drug-related AEs624
Drug-related AEs, Grades 3 and 4424
PrimaryMTD and Recommended MTD of Bortezomib in Combination With Dasatinib and Dexamethasone

MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity in at least 2 out of 6 or fewer participants in that cohort. If MTD is not reached, the recommended dose is the maximum dose that the participants received.

Time frame:
Days 1 to 21
Reported as:
Number · mg/m^2
MTD and Recommended MTD of Bortezomib in Combination With Dasatinib and Dexamethasone
mg/m^2All Treated
MTD of bortezomibNA
Recommended MTD of bortezomib1.3

Adverse events

Collected over Continuously from Day 1 until last day of study medication + 30 days (maximum reached: 10 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dasatinib, 100 mg QD—2/3 (66.7%)3/3 (100%)
Dasatinib, 140 mg QD—1/4 (25%)4/4 (100%)
Dasatinib, 50 mg BID—6/7 (85.7%)6/7 (85.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventDasatinib, 100 mg QDDasatinib, 140 mg QDDasatinib, 50 mg BID
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/43/7
PyrexiaGeneral disorders1/30/40/7
Respiratory tract infectionInfections and infestations1/30/40/7
Confusional statePsychiatric disorders1/30/40/7
DyspnoeaRespiratory, thoracic and mediastinal disorders0/30/42/7
AnaemiaBlood and lymphatic system disorders0/31/40/7
Haemorrhoidal haemorrhageGastrointestinal disorders0/31/40/7
Pneumocystis jiroveci pneumoniaInfections and infestations0/30/41/7
DehydrationMetabolism and nutrition disorders0/30/41/7
Renal failureRenal and urinary disorders0/30/41/7
Most frequent other events
Showing 10 of 57
Most frequent other events
EventDasatinib, 100 mg QDDasatinib, 140 mg QDDasatinib, 50 mg BID
DiarrhoeaGastrointestinal disorders0/33/41/7
AnaemiaBlood and lymphatic system disorders2/31/42/7
ThrombocytopeniaBlood and lymphatic system disorders2/31/41/7
NauseaGastrointestinal disorders0/30/44/7
PyrexiaGeneral disorders0/31/43/7
Abdominal painGastrointestinal disorders1/30/40/7
ConstipationGastrointestinal disorders1/30/40/7
Dry mouthGastrointestinal disorders1/30/40/7
DyspepsiaGastrointestinal disorders1/31/40/7
DysphagiaGastrointestinal disorders1/30/40/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Dasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QDTotal
Mean72 (64.0 to 74.0)74 (57.0 to 75.0)59.5 (53.0 to 75.0)71 (53.0 to 75.0)
Age, Customized
Age, Customized(Participants)Dasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QDTotal
46 to 65 years1135
66 to 75 years6219
Older than 75 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Dasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QDTotal
Female2136
Male5218
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dasatinib, 50 mg BIDDasatinib, 100 mg QDDasatinib, 140 mg QDTotal
White63413
Black or African American0000
American Indian or Alaska Native0000
Native Hawaiian or Other Pacific Islander0000
Asian0000
Other1001
Not reported0000
08

Study locations

7 sites
  • Orlando Health, Inc. M.D. Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • Local Institution
    Nantes, Cedex 1 44093, France
  • Local Institution
    Lille Cedex, 59037, France
  • Local Institution
    Bari, 70124, Italy
  • Local Institution
    Bologna, 40138, Italy
  • Local Institution
    Salamanca, 37007, Spain
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2007
First posted
Nov 19, 2007
Start
Feb 2008
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results first posted
Jul 9, 2012
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00560352
Responsible party
Sponsor
First posted
Nov 19, 2007
Start date
Feb 2008
Primary completion
Feb 2011
Completion
Feb 2011
Results posted
Jul 9, 2012
Last update
Mar 13, 2017

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dasatinib · Bortezomib · Dexamethasone

Start the discussion